SCHEMBL13615138

SCHEMBL13615138

COc1cccc(S(=O)(=O)Nc2ccc(C(C)(C)C)c(F)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 6/20 0.58
RORA P35398 1/20 0.58
RORC P51449 1/20 0.58
NR1H2 P55055 1/20 0.58
GAA P10253 1/20 0.53
ALDH1A1 P00352 2/20 0.52
LMNA P02545 2/20 0.52
AURKA O14965 1/20 0.52
KDR P35968 1/20 0.52
AURKB Q96GD4 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
FFAR4 Q5NUL3 1/20 0.51
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
BRD4 O60885 1/20 0.49
PTPN2 P17706 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615069 0.86 PGR (0.60) PGRRORARORCNR1H2GAA
SCHEMBL13615156 0.86 FFAR4 (0.60) PGRGAAALDH1A1LMNAMAPK1
SCHEMBL13852843 0.84 KMT2A (0.53) PGRGAAALDH1A1LMNAHTT
SCHEMBL13615211 0.82 PKM (0.60) PGRALDH1A1LMNAKDRAURKB
SCHEMBL13615168 0.81 HSD17B2 (0.61) PGRGAAMAPK1FFAR4PTPN2
SCHEMBL13629409 0.81 PGR (0.60) PGRRORARORCNR1H2GAA
SCHEMBL13852840 0.81 SMN1; SMN2 (0.65) GAAALDH1A1LMNAMAPK1ALPL
SCHEMBL13852848 0.78 SLC22A12 (0.54) LMNAHTTBRD4PTPN2PTPN1
SCHEMBL3758000 0.76 PGR (0.83) PGRRORARORCNR1H2GAA
SCHEMBL13615171 0.76 MEN1 (0.48) PGRALDH1A1LMNAHTTFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PGR 1506/4885RORA 2467/4885RORC 1973/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PGR 1648/4885RORA 2358/4885RORC 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.